Drug Pricing Hearing Takes A Partisan Turn As Gilead’s O’Day Holds His Own
Executive Summary
Republicans took off the gloves at House oversight hearing on PrEP, arguing Democrats are more interested in scoring political points than seeking policy solutions to high drug costs.
You may also be interested in...
Descovy, Truvada And The Politics Of PrEP
US FDA's advisory committee review of Gilead’s Descovy for pre-exposure prophylaxis of HIV wasn’t exactly free of controversy. But the meeting sure went more smoothly than the first PrEP review seven years ago.
Gilead’s Marketing Of Descovy For HIV Prevention Should Not Suggest Superiority To Truvada
US FDA advisory committee members urge agency to hold a firm line against labeling, promotional or educational materials that suggest Descovy has better efficacy or is safer than Truvada, which will face generic competition in 2020. Panel backs HIV pre-exposure prophylaxis indication for Descovy but recommends excluding cisgender women due to lack of clinical efficacy data.
Drug Pricing And The AOC Effect
Alexandria Ocasio-Cortez’ social media celebrity gives the first-year Democratic member of Congress an outsize influence – and she is making pharmaceutical industry profits a priority target. But she is also having a unifying effect in rallying Republicans behind industry.